Evidence map›Paper›PMID 34384806›Full record

ArticleAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2022

Atherosclerotic Renovascular Disease: A KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference.

Caitlin W Hicks, Timothy W I Clark, Christopher J Cooper, Áine M de Bhailís, Marco De Carlo, Darren Green, Jolanta Małyszko, Marius Miglinas, Stephen C Textor, Charles A Herzog and 3 more

Open access · greenAbstract read
In one paragraph

Article in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Contemporary Trends in Disparities for Renal Artery Stenting and Angioplasty in the United States.Journal of the Society for Cardiovascular Angiography & Interventions · 2026
    Article
  9. Article
  10. Article
  11. The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025).Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  12. 2024 Thai guidelines on the treatment of hypertension.Asian biomedicine : research, reviews and news · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 6 countries.

Caitlin W HicksDivision of Vascular Surgery and Endovascular Therapy, Johns Hopkins University School of Medicine, Baltimore, MD.
Timothy W I ClarkDivision of Interventional Radiology, Department of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Christopher J CooperCollege of Medicine and Life Sciences, The University of Toledo, Toledo, OH.
Áine M de BhailísDepartment of Renal Medicine, Salford Royal Hospital, Salford, United Kingdom.
Marco De CarloCardiothoracic and Vascular Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Darren GreenDepartment of Renal Medicine, Salford Royal Hospital, Salford, United Kingdom.
Jolanta MałyszkoDepartment of Nephrology, Dialysis, and Internal Medicine, Warsaw Medical University, Warsaw, Poland.
Marius MiglinasCentre of Nephrology, Vilnius University, Santaros Klinikos, Vilnius, Lithuania.
Stephen C TextorDivision of Nephrology and Hypertension, Mayo Clinic, Rochester.
Charles A HerzogChronic Disease Research Group, Hennepin Healthcare Research Institute, University of Minnesota, Minneapolis, MN; Divisions of Cardiology, University of Minnesota, Minneapolis, MN; Hennepin Healthcare; Department of Medicine, University of Minnesota, Minneapolis, MN.
Kirsten L JohansenNephrology, University of Minnesota, Minneapolis, MN; Division of Nephrology, University of Minnesota, Minneapolis, MN.
Holger ReineckeDepartment of Cardiology I: Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Münster, Münster, Germany.
Philip A KalraDepartment of Renal Medicine, Salford Royal Hospital, Salford, United Kingdom. Electronic address: philip.kalra@nca.nhs.uk.
Salford Royal Hospital · GBUniversity of Minnesota · USAzienda Ospedaliera Universitaria Pisana · ITJohns Hopkins Medicine · USMayo Clinic · USMedical University of Warsaw · PLUniversity Hospital Münster · DEUniversity of Pennsylvania · USUniversity of Toledo · USVilnius University · LT

Funding

Risk Factors and Outcomes Associated with Late-Life Diabetic Peripheral NeuropathyK23DK124515 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI HICKS, CAITLIN WHITNEY · 2020 to 2024
$898k
NIDDK NIH HHS K23 DK124515
6 · The paper itself

Abstract

The diagnosis and management of atherosclerotic renovascular disease (ARVD) is complex and controversial. Despite evidence from the ASTRAL (2009) and CORAL (2013) randomized controlled trials showing that percutaneous renal artery revascularization did not improve major outcomes compared with best medical therapy alone over 3-5 years, several areas of uncertainty remain. Medical therapy, including statin and antihypertensive medications, has evolved in recent years, and the use of renin-angiotensin-aldosterone system blockers is now considered the primary means to treat hypertension in the setting of ARVD. However, the criteria to identify kidneys with renal artery stenosis that have potentially salvageable function are evolving. There are also data suggesting that certain high-risk populations with specific clinical manifestations may benefit from revascularization. Here, we provide an overview of the epidemiology, diagnosis, and treatment of ARVD based on consensus recommendations from a panel of physician experts who attended the recent KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference on central and peripheral arterial diseases in chronic kidney disease. Most focus is provided for contentious issues, and we also outline aspects of investigation and management of ARVD that require further research.

Indexed as

AtherosclerosisHypertension, RenovascularRenal Artery ObstructionHumansKidneyRenal ArteryRenin-Angiotensin SystemAtherosclerotic renovascular disease (ARVD)blood pressure controlchronic kidney disease (CKD)fibromuscular dysplasia (FMD)heart failure (HF)ischemic nephropathyRAAS blockaderenal artery stenosis (RAS)renin-angiotensin-aldosterone system (RAAS)revascularizationtreatment recommendations

Identifiers

PMID34384806
PMCPMC9834909
OpenAlexW3190173874

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.